TRCT
TAK icon

Tower Research Capital (TRC)’s Takeda Pharmaceutical TAK Stock Holding History

Tower Research Capital (TRC)’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$4.68K – 5550
2025
Q4 		$4.68K Sell
300
-730
-71% -$10.4K ﹤0.01% 4189
2025
Q3 		$15.1K Sell
1,030
-25,270
-96% -$375K ﹤0.01% 3561
2025
Q2 		$407K Buy
26,300
+13,700
+109% +$202K 0.01% 1159
2025
Q1 		$187K Sell
12,600
-8,298
-40% -$116K 0.01% 1413
2024
Q4 		$277K Buy
20,898
+16,826
+413% +$231K 0.01% 1473
2024
Q3 		$57.9K Sell
4,072
-2,421
-37% -$34.3K ﹤0.01% 2643
2024
Q2 		$84K Buy
6,493
+5,233
+415% +$69.3K ﹤0.01% 2704
2024
Q1 		$17.5K Sell
1,260
-5,490
-81% -$79.8K ﹤0.01% 3117
2023
Q4 		$96.3K Buy
6,750
+4,626
+218% +$65.6K ﹤0.01% 2669
2023
Q3 		$32.9K Sell
2,124
-242
-10% -$3.75K ﹤0.01% 2949
2023
Q2 		$37.2K Sell
2,366
-470
-17% -$7.7K ﹤0.01% 2833
2023
Q1 		$47K Buy
2,836
+527
+23% +$8.39K ﹤0.01% 2555
2022
Q4 		$36K Buy
+2,309
New +$32.3K ﹤0.01% 2594
2022
Q3 		– Sell
-11,938
Closed -$168K – 6476
2022
Q2 		$168K Buy
11,938
+8,184
+218% +$117K ﹤0.01% 1906
2022
Q1 		$54K Buy
+3,754
New +$55.1K ﹤0.01% 2671
2021
Q3 		– Sell
-10,165
Closed -$171K – 6158
2021
Q2 		$171K Sell
10,165
-13,810
-58% -$235K ﹤0.01% 2035
2021
Q1 		$438K Buy
23,975
+23,775
+11,888% +$428K 0.01% 1351
2020
Q4 		$4K Sell
200
-450
-69% -$7.89K ﹤0.01% 4730
2020
Q3 		$12K Sell
650
-1,792
-73% -$32.6K ﹤0.01% 4033
2020
Q2 		$44K Buy
2,442
+2,427
+16,180% +$43.6K ﹤0.01% 3144
2020
Q1 		$0 Sell
15
-10,396
-100% -$188K ﹤0.01% 3861
2019
Q4 		$205K Buy
+10,411
New +$199K 0.02% 568
2019
Q3 		– Sell
-1,898
Closed -$34K – 4500
2019
Q2 		$34K Buy
1,898
+1,858
+4,645% +$33.8K ﹤0.01% 1832
2019
Q1 		$1K Buy
+40
New +$805 ﹤0.01% 3627

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s TAK Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 300 shares — an estimated $4.68K sold.

Tower Research Capital (TRC) first reported a position in TAK in Q1 2019 and held it in 24 quarters. The position peaked at $438K in Q1 2021. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 300 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.68K.
  • Tower Research Capital (TRC) first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s Takeda Pharmaceutical position peaked at $438K in Q1 2021.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.